In June 2017, the EC (European Commission) approved Pfizer’s (PFE) Besponsa as a monotherapy for the treatment of adult individuals with relapsed or refractory CD22-positive B-Cell precursor ALL (acute lymphoblastic leukemia). The approval includes usage for individuals with Philadelphia chromosome-positive and Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL.
The FDA (US Food and Drug Administration) has granted Besponsa a “breakthrough therapy” designation for the treatment of ALL in October 2015. The FDA has accepted Pfizer’s BLA (biologics license application), and a PDUFA (Prescription Drug User Fee Act) action date has been provided for August 2017.
In July 2017, Pfizer entered into an agreement with Basilea Pharmaceuticals for Cresemba’s exclusive commercialization rights in Europe. Cresemba (isavuconazole) is indicated for the treatment of adults diagnosed with aspergillosis and mucormycosis.
In May 2017, the EC approved Trumenba, a meningococcal group-B vaccine, for the prevention of invasive meningococcal disease triggered by Neisseria meningitidis serogroup-B. The vaccine is indicated for administration to individuals older than ten.
Recent regulatory approvals and filing should boost Pfizer’s revenue growth. Notably, the SPDR SSGA Gender Diversity Index ETF (SHE) has ~6.2% of its total portfolio holdings in Pfizer.
Of the 22 analysts analyzing Pfizer in July 2017, one recommended a “strong buy,” while ten recommended a “buy.” Ten analysts analyzing Pfizer recommended a “hold,” while one analyst recommended a “strong sell.”
Around ~50% of these analysts have recommended some form of “buy.”
Of the 22 analysts covering Eli Lilly (LLY) in July 2017, five suggested a “strong buy.” Ten recommended a “buy,” while six recommended a “hold.” One analyst recommended a “sell,” while none of the analysts suggested a “strong sell.”
Around 68% of the analysts covering Eli Lilly suggested some form of “buy.”
Of the 32 analysts analyzing Novartis (NVS) in July 2017, six suggested a “strong buy,” while nine suggested a “buy.” Fourteen analysts recommended a “hold,” while three recommended a “sell.”
Around ~47% of the analysts covering NVS have recommended some form of “buy.”
Of the 24 analysts covering Amgen (AMGN) in July 2017, four recommended a “strong buy,” while seven recommended a “buy,” and 13 recommended a “hold.”
No analyst has recommended any form of “sell” for Pfizer stock.